DFTX - Mind Medicine (MindMed) Inc.

17.66
0.110   0.623%

Share volume: 957,319
Last Updated: 03-06-2026
Pharmaceutical Products/Medicinal Chemicals: 2.19%

PREVIOUS CLOSE
CHG
CHG%
$17.55
0.11
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 50%
Dept financing 37%
Liquidity 45%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.17%
1 Month
1.79%
3 Months
35.85%
6 Months
88.07%
1 Year
180.32%
2 Year
82.06%
Key data
Stock price
$17.66
P/E Ratio 
0.00
DAY RANGE
$16.87 - $17.90
EPS 
-$2.06
52 WEEK RANGE
$4.70 - $18.70
52 WEEK CHANGE
$180.32
MARKET CAP 
1.319 B
YIELD 
N/A
SHARES OUTSTANDING 
99.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,976,877
AVERAGE 30 VOLUME 
$1,458,337
Company detail
CEO: Robert Barrow
Region: US
Website: mindmed.co
Employees: 40
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Recent news